{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:05:50Z","timestamp":1791378350235,"version":"4.3.2"},"reference-count":10,"publisher":"Centers for Disease Control and Prevention - Preventing Chronic Disease","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prev. Chronic Dis."],"DOI":"10.5888\/pcd23.260181","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:42:55Z","timestamp":1791376975000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Community Pharmacies in Creating Harm Reduction Infrastructure to Address the US Opioid Crisis"],"prefix":"10.5888","volume":"23","author":[{"given":"Isaiah","family":"Ratz","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Woinarowicz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Eukel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54162","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"2","key":"key-10.5888\/pcd23.260181-202609281207-R1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jama.2025.7795","article-title":"US drug overdose deaths dropped nearly 27% last year","volume":"334","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"key-10.5888\/pcd23.260181-202609281207-R2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1515195","article-title":"HIV infection linked to injection use of oxymorphone in Indiana, 2014\u20132015","volume":"375","author":"Peters","year":"2016","journal-title":"NEJM"},{"key":"key-10.5888\/pcd23.260181-202609281207-R3","doi-asserted-by":"publisher","first-page":"102727","DOI":"10.1016\/j.drugpo.2020.102727","article-title":"Rural risk environments, opioid-related overdose, and infectious diseases: a multidimensional, spatial perspective","volume":"85","author":"Kolak","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"2","key":"key-10.5888\/pcd23.260181-202609281207-R4","doi-asserted-by":"publisher","first-page":"e1921227","DOI":"10.1001\/jamanetworkopen.2019.21227","article-title":"Availability of naloxone at rural Georgia pharmacies, 2019","volume":"3","author":"Nguyen","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"key-10.5888\/pcd23.260181-202609281207-R5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/cid\/cix333","article-title":"Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States","volume":"65","author":"Canary","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"key-10.5888\/pcd23.260181-202609281207-R6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/08897077.2017.1391924","article-title":"Barriers and facilitators to dispensing of intranasal naloxone by pharmacists","volume":"39","author":"Bakhireva","year":"2018","journal-title":"Subst Abus"},{"issue":"1","key":"key-10.5888\/pcd23.260181-202609281207-R7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12954-025-01280-2","article-title":"Sterile syringe availability in Georgia pharmacies remained rare, despite policy change permitting sales","volume":"22","author":"Yarbrough","year":"2025","journal-title":"Harm Reduct J"},{"key":"key-10.5888\/pcd23.260181-202609281207-R8","doi-asserted-by":"publisher","first-page":"102602","DOI":"10.1016\/j.drugpo.2019.11.010","article-title":"Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy","volume":"85","author":"Green","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"3","key":"key-10.5888\/pcd23.260181-202609281207-R9","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2468-2667(21)00304-2","article-title":"Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study","volume":"7","author":"Irvine","year":"2022","journal-title":"Lancet Public Health"},{"issue":"5","key":"key-10.5888\/pcd23.260181-202609281207-R10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.sapharm.2019.08.026","article-title":"Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C","volume":"16","author":"Meyerson","year":"2020","journal-title":"Res Social Adm Pharm"}],"container-title":["Preventing Chronic Disease"],"original-title":[],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:42:55Z","timestamp":1791376975000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/pcd\/issues\/2026\/26_0181.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":10,"URL":"https:\/\/doi.org\/10.5888\/pcd23.260181","relation":{},"ISSN":["1545-1151"],"issn-type":[{"value":"1545-1151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"article-number":"260181"}}